Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  BioMarin Pharmaceutical Inc.    BMRN   US09061G1013

SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo BioMarin Pharmaceutical In
Discovers, develops and commercializes innovative pharmaceuticals for serious diseases & medical conditions

BioMarin Pharmaceutical, Inc. develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions.

The company operates its business through one segment, the biopharmaceutical development and commercialization segment.

Its company's product portfolio is comprised of five approved products and multiple investigational product candidates which include Naglazyme, Kuvan, Aldurazyme, Firdapse and VIMIZIM.

Naglazyme is a recombinant form of N-acetylgalactosamine 4-sulfatase indicated for patients with ucopolysaccharidosis VI. MPS VI is a debilitating life-threatening genetic disease for which no other drug treatment currently exists and is caused by the deficiency of arylsulfatase B, an enzyme normally required for the breakdown of certain complex carbohydrates known as glycosaminoglycans, or GAGs.

Kuvan is a proprietary synthetic oral form of 6R-BH4, a naturally occurring enzyme co-factor for phenylalanine hydroxylase, indicated for patients with PKU, which is an inherited metabolic disease that affects patients under the age of 40 in the developed world.

Aldurazyme has been approved for marketing in the U.S., EU and other countries for patients with mucopolysaccharidosis.

Firdapse is a form of 3, 4-diaminopyridine for the treatment of Lambert Myasthenic Syndrome.

And VIMIZIM is an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder.

The company was founded on March 21, 1997 and is headquartered in Novato, CA.
Managers
NameAgeSinceTitle
Pierre LaPalme732004Chairman
Robert A. Baffi PhD, MBA592000Executive Vice President-Technical Operations
Elaine J. Heron PhD, MBA662002Independent Non-Executive Director
Jean-Jacques Bienaimé, MBA602005Chief Executive Officer & Director
Joshua A. Grass, MBA-2002Senior VP-Business & Corporate Development
Mike G. Grey612005Independent Non-Executive Director
Richard A. Meier542006Independent Non-Executive Director
V. Bryan Lawlis Jr., PhD612007Independent Non-Executive Director
Alan J. Lewis, PhD682005Independent Non-Executive Director
Jeffrey Robert Ajer, MBA512005Chief Commercial Officer & Executive VP
Shareholders
Sector
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Generic Pharmaceuticals
Advertisement
Surperformance© rating
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
PER -
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
More Ratings
Sector Pharmaceuticals
Growth (Revenue) Profitability
SUN PHARMACEUTICA..
OTSUKA HOLDINGS C..
ASPEN PHARMACARE ..
BIOMARIN PHARMACE..
ONO PHARMACEUTICA..
ENDO INTERNATIONA..
HOSPIRA, INC.
SHANGHAI FOSUN PH..
SIHUAN PHARMACEUT..
CIPLA LTD
TAISHO PHARMACEUT..
CADILA HEALTHCARE..
XIZANG HAISCO PHA..
LUYE PHARMA GROUP..
-
CHINA MEDICAL SYS..
DIVI'S LABORATORI..
SHENZHEN SALUBRIS..
SICHUAN KELUN PHA..
-
GLENMARK PHARMACE..
RICHTER GEDEON VE..
Sector Pharmaceuticals
Company contact information
BioMarin Pharmaceutical, Inc.
770 Lindaro Street
San Rafael, CA 94901

Phone : +1.415.506.6700
Web : www.bmrn.com
© 2014 Factset   
Dynamic quotes  
ON
| OFF